Document is current
Any future updates will be listed below
-
Authors
Goupille, Philippe https://orcid.org/0000-0002-8605-1567
Carvajal Alegria, Guillermo
Verhoeven, Frank
Wendling, Daniel
- License Information
-
More Information
Article History
Received: 5 June 2024
Accepted: 18 July 2024
First Online: 12 August 2024
Declarations
:
: Philippe Goupille: Financial interests/Lasting or permanent links: none; Specific interventions: AbbVie, BMS, Galapagos, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, UCB; Indirect interests: Abbvie, Biogen, Pfizer, MSD, UCB, Janssen, Lilly, Novartis. Guillermo Carvajal Alegria: Financial interests/ Lasting or permanent links: none; Specific interventions: Abbvie, BMS, Galapagos, Lilly, MSD, Novartis, Chugai, Pfizer; Indirect interests: Novartis, Lilly, Abbvie, Biogen, Fresenius-Kabi. Frank Verhoeven: Financial interests/ Lasting or permanent links: none; Specific interventions: AbbVie, BMS, Galapagos, Janssen, Lilly, MSD, Novartis, Chugai, UCB; Indirect interests: Novartis. Daniel Wendling: Financial interests/ Lasting or permanent links: none; Ad hoc interventions: AbbVie, BMS, MSD, Pfizer, Roche Chugai, Amgen, Nordic Pharma, UCB, Novartis, Janssen, Celgene, Lilly, Galapagos; Indirect interests: Abbvie, Pfizer, Roche Chugai, MSD, UCB, Mylan, Fresenius Kabi.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
